Cancer Treatment Reviews
Volume 27, Issue 4 , Pages 211-220 , August 2001

New options for outpatient chemotherapy – the role of oral fluoropyrimidines

  • D. Cunningham

      Affiliations

    • Department of Medicine, The Royal Marsden Hospital, London and Surrey, UK
    • ,
  • R. Coleman

      Affiliations

    • Yorkshire Cancer Research Department of Clinical Oncology, Weston Park Hospital NHS Trust, Whitham Road, Sheffield, UK

References 

    REFERENCES
  1. Grem JL. 5-fluoropyrimidines. In:  Chabner BA,  Longo DL editor. Cancer chemotherapy and biotherapy: principles and practice. Philadelphia: Lippincott-Raven; 1996;p. 149–211
  2. Hortobagyi GN. Treatment of breast cancer. N Engl J Med. 1998;339:974–984
  3. Kamm YJL, Wagener DJT, Reitjens IMCM, Punt CJA. 5- fluorouracil in colorectal cancer: rationale and clinical results of frequently used schedules. Anti Cancer Drugs. 1998;9:371–380
  4. Schmoll HJ. Development of treatment for advanced colorectal cancer: infusional 5-FU and the role of new agents. Eur J Cancer. 1996;32A:S18–S22
  5. Lokich JL, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a mid-Atlantic Oncology program study. J Clin Oncol. 1989;7:425–432
  6. Bleiberg H. Colorectal cancer: the challenge. Eur J Cancer. 1996;32A:2–6
  7. Allegra CJ, Grem JL, DeVita VT, Hellman S, Rosenberg SA. Antimetabolites. Cancer, principles and practice of oncology. Philadelphia: Lippincott-Raven; 1997; p. 432–452
  8. De Gramont A, Bosset J-F, Milan C, Rougier P, Bouche O, Etienne P-L, et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol. 1997;15:808–815
  9. Schmoll HJ, Köhne CH, Lorenz M, Schffski P, Voigtmann R, Bokemeyer C, et al. Weekly 24 h infusion of high-dose (HD) 5-fluorouracil (5-FU24 h) with or without folinic acid (FA) vs. bolus 5-FU/FA (NCCTG/ Mayo) in advanced colorectal cancer (CRC): a randomized phase III study of the EORTC GITCCG and the AIO. Proc Am Soc Clin Oncol. 2000;19 241a Abstract 935:
  10. J Clin Oncol. 1998;16:301–308
  11. Seifert P, Baker LH, Reed ML, Vaitkevicius VK. Comparison of continuously infused 5-fluorouracil with bolus injection in treatment of patients with colorectal adenocarcinoma. Cancer. 1975;36:123–128
  12. Anderson N, Lokich J. Controversial issues in 5-fluorouracil infusion use. Dose intensity, treatment duration, and cost comparison. Cancer. 1992;70:998–1002
  13. Hansen TM, Ryan L, Anderson T, Krzywda B, Quebbeman E, Benson A, et al. Phase III study of bolus versus infusion fluorouracil with or without cisplatin in advanced colorectal cancer. J Natl Cancer Inst. 1996;88:668–674
  14. Hortobagyi GN, Piccart-Gebhart MJ. Current management of advanced breast cancer. Semin Oncol. 1996;7:1–5
  15. Rothenbacher D, Lutz MP, Porzsolt F. Treatment decisions in palliative cancer care: patients’ preferences for involvement and doctors’ knowledge about it. Eur J Cancer. 1997;33:1184–1189
  16. Redmond K. Assessing patients’ needs and preferences in the management of advanced colorectal cancer. Br J Cancer. 1998;77:5–7
  17. Ravdin PM, Siminoff IA, Harvey JA. Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy. J Clin Oncol. 1998;16:515–521
  18. Topham C, Moore J. Patient preferences for chemotherapy schedules used in the treatment of advanced colorectal cancer – a pilot study. Eur J Cancer Care. 1997;6:291–294
  19. Liu G, Franssen E, Fitch M, Warner E. Patient preferences for oral versus intravenous palliative chemotherapy. J Clin Oncol. 1997;15:110–115
  20. Borner M, Schöffski P, de Wit R, Caponigro F, Comella G, Sulkes A, et al. A randomized crossover trial comparing oral UFT (uracil/tegafur) + leucovorin (LV) and intravenous fluorouracil (FU) + LV for patient preference and pharmacokinetics in advanced colorectal cancer. Proc Am Soc Clin Oncol. 2000;19:
  21. Payne SA. A study of quality of life in cancer patients receiving palliative chemotherapy. Soc Sci Med. 1992;35:1505–1509
  22. Carison RW. Quality of life issues in the treatment of metastatic breast cancer. Oncology. 1998;12:27–31
  23. DeMario MD, Ratain MJ. Oral chemotherapy: rationale and future directions. J Clin Oncol. 1998;16:2557–2567
  24. Rustum YM, Marstrick A, Cao S, Vanhoefer U, Yin M-B, Wilke H, et al. Thymidylate synthase inhibitors in cancer therapy: direct and indirect inhibitors. J Clin Oncol. 1997;15:389–400
  25. Punt C. New drugs in the treatment of colorectal carcinoma. Cancer. 1998;83:679–689
  26. Schilsky RL, Hohneker J, Ratain MJ, Crawford J, Hochster H, O’Rourke M, et al. Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer. J Clin Oncol. 1998;16:1450–1457
  27. Baker SD, Diasio RB, O’Reilly S, Lucas VS, Khor SP, Sartorius SE, et al. Phase I and pharmacologic study of oral fluorouracil on a chronic daily schedule in combination with the dihydropyrimidine dehydrogenase inactivator eniluracil. J Clin Oncol. 2000;18:915–926
  28. Pazdur R, Lassere Y, Diaz Canton E, Bready B. Phase I trial of uracil-tegafur (UFT) using 5 and 28 day administration schedules: demonstration of schedule dependent toxicities. Anti-Cancer Drugs. 1996;7:728–733
  29. Pazdur R, Hoff PM, Medgyesy D, Royce M, Brito RA. The oral fluorouracil prodrugs. Oncology. 1998;12:48–51
  30. van Groeningen CJ, Peters GJ, Schornagel JH, Gall H, Noordhuis P, de Vries MJ, et al. Phase I clinical and pharmacokinetic study of oral S-1 in patients with advanced solid tumors. J Clin Oncol. 2000;18:2772–2779
  31. Mackean M, Planting A, Twelves C, Schellens J, Allman D, Osterwalder B, et al. Phase I and pharmacologic study of intermittent twice daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J Clin Oncol. 1998;16:2977–2985
  32. Cassidy J, Dirix L, Bissett D, Reigner B, Griffin T, Allman D, et al. A phase I study of capecitabine in combination with oral leucovorin in patients with intractable solid tumors. Clin Cancer Res. 1998;4:2755–2761
  33. Schilsky RL, Bukowski R, Burris H, Hochster H, O’Rourke M, Wall JG, et al. A multicenter phase II study of a five-day regimen of oral 5-fluorouracil plus eniluracil with or without leucovorin in patients with metastatic colorectal cancer. Ann Oncol. 2000;11:415–420
  34. Mani S, Hochster H, Beck T, Chevlen EM, O’Rourke MA, Weaver CH, et al. Multicenter phase II study to evaluate a 28-day regimen of oral fluorouracil plus eniluracil in the treatment of patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2000;18:2894–2901
  35. Smith IE, Johnston SRD, O’Brien MER, Hickish TF, de Boer RH, Norton A, et al. Low-dose oral fluorouracil with eniluracil as first-line chemotherapy against advanced breast cancer: a phase II study. J Clin Oncol. 2000;18:2378–2384
  36. Skovsgaard T, Davidson N, Piccart MJ, Richel DJ, Harris DT, Barton C. Promising activity with eniluracil (776C85) and oral 5-fluorouracil in patients with anthracycline-refractory or anthracycline- and taxane-refractory advanced breast cancer: a phase II study. Eur J Cancer. 1999;35:
  37. Blum J, Jones S, Buzdar A, LoRusso P, Kuter I, Vogel C, et al. Multicenter phase II study of capecitabine in paclitaxel-refractory metastatic breast cancer. J Clin Oncol. 1999;17:485–493
  38. Blum, J. L. Dieras, V. LoRusso, P. M. Horton, J. Rutman, O. Buzdar, A. Osterwalder, B. Multicenter, phase II study of capecitabine in taxane-pretreated metastatic breast cancer patients. Cancer
  39. O’Reilly SM, Moiseyenko BV, Talbot DC. A randomized phase II study of Xeloda™ (capecitabine) vs paclitaxel in breast cancer patients failing previous anthracycline therapy. Proc Am Soc Clin Oncol. 1998;17:
  40. Ron IG, Lotan A, Inbar MJ, Chaitchik S. Advanced colorectal carcinoma: redefining the role of oral ftorafur. Anti Cancer Drugs. 1996;7:649–654
  41. Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, et al. Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol. 1994;12:2296–2300
  42. Sanchiz F, Milla A. Tegafur-uracil (UFT) plus folinic acid in advanced rectal cancer. Jpn J Clin Oncol. 1994;24:322–326
  43. Pazdur R, Douillard J-Y, Skillings JR, Eisenberg PD, Davidson N, Harper P. Multicenter phase III study of 5-fluorouracil (5-FU) or UFT™ in combination with leucovorin (LV) in patients with metastatic colorectal cancer. Proc Am Soc Clin Oncol. 1999;18:
  44. Hoff PM. Capecitabine as first-line treatment for colorectal cancer (CRC): integrated results of 1207 patients (pts) from 2 randomized, phase III studies. On behalf of the Capecitabine CRC Study Group. Ann Oncol. 2000;11:
  45. Sugimachi K, Maehara Y, Akazawa K, Nomura Y, Eida K, Ogawa M, et al. Post-operative chemoendocrine treatment with mitomycin C, tamoxifen, and UFT is effective for patients with premenopausal estrogen receptor-positive stage II breast cancer. Breast Cancer Res Treat. 1999;56:113–124
  46. Hirata K, Uchino J, Nomura Y. Tegafur and uracil (UFT®) as post-operative adjuvant chemotherapy for breast cancer – meta-analysis of five clinical studies. Breast Cancer Res Treat. 1999;57:
  47. Taguchi T. Experience with UFT in Japan. Oncology. 1997;11:30–40
  48. Rustum YM, Cao S, Shirasaka T, Taguchi T. A new 5-fluorouracil prodrug, S-1, orally bioavailable with high therapeutic index in model system active in phase II trials. Proc Am Soc Clin Oncol. 1997;16:
  49. Ohtsu A, Baba H, Sakata Y, Mitachi Y, Horikoshi N, Sugimachi K, et al. Phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with metastatic colorectal carcinoma. Br J Cancer. 2000;83:141–145
  50. Miwa M, Ura M, Nishida M, Sawada N, Ishikawa I, Ishitsuka H. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissues. Eur J Cancer. 1998;8:1274–1281
  51. Ishikawa T, Sekiguchi F, Fukase Y, Sawada N, Ishitsuka H. Positive correlation between the efficacy of capecitabine and doxifluridine and the ratio of thymidine phosphorylase to dihydropyrimidine dehydrogenase activities in tumors in human cancer xenografts. Cancer Res. 1998;58:685–690
  52. Schüller J, Cassidy J, Dumont E, Roos B, Durston S, Banken L, et al. Preferential activation of capecitabine in tumor following oral administration in colorectal cancer patients. Cancer Chemother Pharmacol. 2000;45:291–297
  53. Van Cutsem E, Findlay M, Osterwalder B, Kocha W, Dalley D, Pazdur R, et al. Capecitabine (Xeloda™), an oral fluoropyrimidine carbamate with substantial activity in advanced colorectal cancer: results of a randomized phase II study. J Clin Oncol. 2000;18:1338–1345
  54. Van Cutsem, E. Twelves, C. Cassidy, J. Oral capecitabine with metastatic colorectal cancer: results of a large phase II study. J Clin Oncol
  55. Hoff PM, Ansar R, Batist G. Comparison of oral capecitabine versus intravenous fluorouracil plus levcovonin as first-line treatment in 605 patients with metastatic colectoral cancer: results of a randomized phase III study. J Clin Oncol. 2001;19:2282–2292
  56. Aapro M. First-line capecitabine treatment for metastatic breast cancer (MBC): updated data from a randomised phase II trial. Proc ICACT. 2000;S4-S10:87
  57. O’Shaughnessy J, Blum J. A retrospective evaluation of the impact of dose reduction in patients treated with Xeloda® (capecitabine). Proc Am Soc Clin Oncol. 2000;19:
  58. O’Shaughnessy J, Vukelja S, Moiseyenko V, Miles D, Cervantes G, Chan Navarro C, et al. Results of a large phase III trial of Xeloda®/Taxotere®combination therapy vs Taxotere®monotherapy in metastatic breast cancer (MBC) patients. Poster presented at the San Antonio Breast Cancer Symposium, San Antonio, USA,. 2000;
  59. Villalona-Calero MA, Weiss GR, Burris HA, Kraynak M, Rodrigues G, Drengler RL, et al. Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. J Clin Oncol. 1999;17:1915–1925
  60. Villalona-Calero MA, Blum JL, Jones SE. A phase I and pharmacologic study of capecitabine and paclitaxel in breast cancer patients. Ann Oncol. 2001;12:605–614
  61. Pronk LC, Vasey P, Sparreboom A, Reigner B, Planting AST, Gordon RJ, et al. A phase I and pharmacokinetic study of the combination of capecitabine and docetaxel in patients with advanced solid tumours. Br J Cancer. 2000;83:22–29
  62. Pérez-Manga G, Batista N, Constenla M, Guillem V, Carabantes F, Ahlgren J, et al. Efficacy and safety profile of capecitabine (Xeloda®) in combination with paclitaxel (P) in patients with locally advanced or metastatic breast cancer: preliminary results of a phase II study. Breast Cancer Res Treat. 2000;64:
  63. Evans J, Tabernero J, Cassidy J, Sastre J, Eatock M, Baselga J, et al. Safety profile and preliminary efficacy of capecitabine (Xeloda®) in combination with oxaliplatin in patients with advanced or metastatic solid tumours: results from a phase I study. Ann Oncol. 2000;11:
  64. Vanhoefer UJ, Mayer S, Achterrath W, Hense J, Omidi S, Frings S, et al. Phase I study of capecitabine in combination with a weekly schedule of irinotecan as first-line chemotherapy in metastatic colorectal cancer. Ann Oncol. 2000;11:
  65. Dunst J, Reese T, Frings S. Phase I study of capecitabine combined with standard radiotherapy in patients with rectal cancer. Proc Am Soc Clin Oncol. 2000;19:
  66. Dorta FJ, Feliú J, Vicent J, Garcia-Gir? C, Constenla M, Fonseca E, et al. Phase II clinical trial with the combination of oxaliplatin-UFT-1, -leucovorin (OXA-UFT-1, LV) for the first line treatment of advanced colorectal cancer (ACC). Ann Oncol. 2000;11:
  67. Hill M, Mackay M, Cunningham D, Glasspool R, Price T, Campbell S, et al. A phase I/II study of oral uracil/tegafur (UFT®) leucovorin and irinotecan in patients with advanced colorectal cancer. Ann Oncol. 2000;11:

PII: S0305-7372(01)90229-4

doi: 10.1053/ctrv.2001.0229

Cancer Treatment Reviews
Volume 27, Issue 4 , Pages 211-220 , August 2001

Article Tools